|
|
Biotech
|
|
||
GLYCThe company has $200 m in cash, with possible large milestone payments from Pfizer if Rivipansel succeed with results expected in the next few months, and they only spend about 15 m per quarter. They are good till 2023. So why do they filed for a secondary of $250M, increasing the share count by 50% ? And in the prospectus they state that they have no acquisition in sight. I do not own GLYC, but I am curious, comments on GLYC ? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
27347 | Re: GLYC | Biotech_Jim | 10 | 5/19/2019 10:38:03 PM |
27349 | Re: GLYC | CHM_760 | 6 | 5/20/2019 7:19:18 AM |